Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler
Launched by UNIVERSITY HOSPITAL HEIDELBERG · Jan 2, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how often patients develop a condition called postoperative pancreatic fistula (POPF) after having a surgery called distal pancreatectomy (DP). This surgery involves removing part of the pancreas, and the trial specifically uses a device called the AEON™ Endostapler. The study will include 110 patients and aims to gather information that could help surgeons improve techniques, reduce complications, and enhance overall health outcomes for patients undergoing this type of surgery.
To participate in this trial, patients need to be at least 18 years old and able to understand the study details and provide written consent. They should be scheduled for a DP surgery, whether through minimally invasive techniques or open surgery. However, those who have had previous pancreatic surgeries or are involved in other conflicting trials won't be eligible. Participants can expect to be followed closely during recovery to monitor for any complications and to help improve future surgical practices.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 years or older.
- • Ability to understand the nature and consequences of the study.
- • Provision of written informed consent.
- • Scheduled for minimally invasive or open distal pancreatectomy (DP) for any indication, with or without splenectomy and/or left adrenalectomy.
- Exclusion Criteria:
- • Inability to comply with study procedures or follow-up.
- • Multivisceral resection beyond left adrenalectomy.
- • History of previous pancreatic surgeries.
- • Expected lack of compliance with the study protocol.
- • Participation in another trial that may interfere with the intervention or outcomes of this study.
About University Hospital Heidelberg
University Hospital Heidelberg is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key player in translational medicine, the hospital integrates cutting-edge scientific discoveries with patient care, facilitating a robust environment for clinical trials. With a diverse range of specialties and a multidisciplinary approach, University Hospital Heidelberg aims to improve therapeutic outcomes and enhance the quality of life for patients through evidence-based practices. The institution is dedicated to fostering collaborations with academic partners, industry stakeholders, and regulatory bodies to drive forward-looking research initiatives and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, , Germany
Heidelberg, Baden Württemberg, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported